

Biochim Biophys Acta 1994; 1191: 384-8.

11 Bouchelouche P, Friche E, Sehested M, Jensen PB, Skovsgaard T
Cytosolic free Ca²⁺ in daunorubicin and vincristine resistant Ehrlich
ascites tumor cells. Drug accumulation is independent of
intracellular Ca²⁺ changes.

Biochem Pharmacol 1991; 41: 243-53

77-80

2-苯-3-(3',5'-双吗啉甲基-4'-羟基)-苯甲酰咪唑 (HWL-12)逆转肿瘤多药抗药性

符立梧¹, 潘启超¹, 黄文龙², 杨小平

(¹中山医科大学肿瘤研究所, 广州 510060, 中国; ²中国
药科大学药化研究室, 南京 210009, 中国)

R730.53
R915

肿瘤

关键词 多种抗药性; 咪唑类; HWL-12; 阿霉素;

Fura-2; 钙; 培养的肿瘤细胞; 维拉帕米; 依他酸

目的: 探讨咪唑衍生物 HWL-12 逆转 MDR 的作用
及其作用机制. 方法: 细胞毒的测定用 MTT 法;
P-糖蛋白的测定用我们新近建立的 Fura 2-AM 法.
细胞内阿霉素(Dox)的积累测定用荧光分光光度
计法. 结果: HWL-12 能显著地增加 MDR 细胞内
Fura-2 的积累和逆转 MDR 17.2 倍. 在 HWL-12
的作用下, MDR 细胞内阿霉素的积累亦明显增
加, 但在介质中高钙或低钙离子浓度对 Dox 积累
均无影响. 结论: HWL-12 具有较强的逆转作用,
它的逆转机制可能与增加 MDR 细胞内阿霉素的
积累有关, 而与钙离子浓度无关.

Effect of catecholamic acid on detoxication and distribution of NiCl₂ in mice and rats¹

YAN Xue-Ming², TAO Zheng-Qin, LIANG You-Yi, CHEN Zhen-Jia, ZHANG Jian-Shi, XU Xin-Hua
(Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China)

KEY WORDS chelating agents; catecholamic acid;
nickel; lethal dose 50; autoradiography; tissue
distribution

AIM: To study the effect of catecholamic acid
(CBMIDA) on detoxication of NiCl₂. **METHODS:**
Mice and rats were injected sc or im CBMIDA
immediately after ip NiCl₂. Each mouse was injected
ip CBMIDA after iv ⁶³NiCl₂ 185 kBq, and
radioactivities of various tissues were measured with
liquid scintillation counter at 24 h. The localization of
⁶³Ni was shown by the whole-body autoradiography.
RESULTS: CBMIDA sc 0.5-1.5 g·kg⁻¹ markedly
reduced the mortality from acute poisoning of ip NiCl₂
500 mg·kg⁻¹. After ip NiCl₂ in mice, the LD₅₀ was
82.7 mg·kg⁻¹. Mice were injected sc CBMIDA 1.5
or 2.5 g·kg⁻¹ after Ni poisoning, the LD₅₀ of NiCl₂
were raised to 789 or 820 mg·kg⁻¹, respectively.

The LD₅₀ of NiCl₂ was 39 mg·kg⁻¹ in rat. If
CBMIDA was injected im 0.5 g·kg⁻¹ after ip NiCl₂,
the LD₅₀ was 332 mg·kg⁻¹. CBMIDA 1.5 g·kg⁻¹
im after iv ⁶³NiCl₂, decreased the contents of ⁶³Ni in
blood and lung of mice vs control mice at 24 h. The
contents of ⁶³Ni in brain, heart, spleen, and kidney
were similar to those of the control mice. The content
of ⁶³Ni in bone was more than the control. The
excretions of ⁶³Ni through urine and feces were not
increased by CBMIDA at 24 h. The whole-body
autoradiography showed that the radioactivity was highly
localized in the kidney, lung, and Harder's gland.
There was a moderate level of ⁶³Ni in the liver, bone,
skin, and blood. A pronounced accumulation
occurred in the bone. There was a marked reduction
of ⁶³Ni in the lung, skin, liver, and blood after ip
CBMIDA. **CONCLUSION:** The CBMIDA
markedly raised the survival rate of nickel-poisoned
mice and rats, and decreased ⁶³Ni levels in lung and
blood.

¹ Project supported by the National Natural Science Foundation of China, No 3870510.


² Phn 86-21-6431-1833, ext 404 Fax 86-21-6437-0269.

Received 1996-12-19

Accepted 1997-09-15

Nickel compounds widely used in industry were absorbed into the body and deposited mainly in lung, so the lungs are the critical organ after exposure to nickel. A long period of exposure to nickel compounds may cause lung cancer^[1], and most chelating agents are ineffective to treat nickel poisoning.

Catecholamic acid [catechol-3,6-bis(methyleneiminodiacetic acid), CBMIDA] first synthesized by Prof XIE Yu-Yuan in our Institute was a chelating agent of a low toxicity^[2], and increased excretion of uranium^[3] and plutonium^[4] in rats.



Catecholamic acid (CBMIDA)

The purpose of the present study was to explore the effects of CBMIDA on detoxication, removal, and tissue distribution of NiCl_2 .

MATERIALS

Kunming mice (\uparrow) and Sprague-Dawley rats (\uparrow) were obtained from Shanghai Experimental Animal Center, Chinese Academy of Sciences, Certificate No 005.

Catecholamic acid was synthesized by Department of Synthetic Chemistry in our Institute, purity >95% and mp 184 °C. It was dissolved in distilled water with the aid of NaHCO_3 , pH 6–7, and prepared before 30 min administration. $\text{NiCl}_2(\text{AR})$ was produced by Shanghai Qingong Chemical Plant. $^{63}\text{NiCl}_2$ was made by the Radiochemical Center Ltd, UK (radioactivity 247 $\text{GBq} \cdot \text{L}^{-1}$). The X-ray film was LKB Ultrafilm S-161 25 Bromma, Sweden. The whole-body section was made on Lipshaw Cryotome 1800-N freezing microtome, USA. Liquid scintillation counter (model YSJ-78) was made by Shanghai Institute of Nuclear Research, Chinese Academy of Sciences.

METHODS AND RESULTS

Detoxication of nickel by CBMIDA Mice (weighing $20.0 \pm s 1.6$ g) injected ip NiCl_2 500 $\text{mg} \cdot \text{kg}^{-1}$ were divided into 5 groups, 20 mice/group. Then the control group mice were injected sc 0.9 %

saline, and other 4 groups were immediately injected sc CBMIDA 0.5, 1, 1.5, and 2 $\text{g} \cdot \text{kg}^{-1}$, respectively. The mortality was recorded within 3 d. The diarrhoea, respiratory distress, and lethargy were noted in toxicity tests. All mice of control group died. In the CBMIDA-treated groups, 0.5–1.5 $\text{g} \cdot \text{kg}^{-1}$, exhibited a dose-response relationship (Tab 1).

Tab 1. Detoxifying effect of sc catecholamic acid (CBMIDA) after ip NiCl_2 500 $\text{mg} \cdot \text{kg}^{-1}$ within 3 d. ^a $P < 0.01$ vs 0; ^b $P > 0.05$, ^c $P < 0.05$ vs 0.5; ^d $P > 0.05$ vs 1.

CBMIDA/ $\text{g} \cdot \text{kg}^{-1}$	Injected mice	Survived mice
0	20	0
0.5	20	13 ^c
1.0	20	17 ^{cd}
1.5	20	20 ^{cd}
2.0	20	20 ^{cd}

Various chelating agents on detoxication of nickel Mice (weighing $19.8 \pm s 1.3$ g, divided into 9 groups, 40 mice/group) were injected ip NiCl_2 70, 150, 250, and 500 $\text{mg} \cdot \text{kg}^{-1}$, ($n = 10$). After nickel poisoning, 7 chelating agents were injected sc: CBMIDA 1.5 or 2.5; sodium dimercaptosuccinate (Na-DMS) 1; quamic acid (QA) 0.5; penicillamine (PCA) 0.3; 1,2-cyclohexylene dinitrilotetraacetic acid (CDTA) 0.15; edetic acid 0.15; dithiocarb (DDC) 0.5 $\text{g} \cdot \text{kg}^{-1}$. CBMIDA remarkably raised the survival rate of mice, as compared with other chelating agents. The effect of CBMIDA 1.5 $\text{g} \cdot \text{kg}^{-1}$ was similar to that of 2.5 $\text{g} \cdot \text{kg}^{-1}$ (Tab 2).

Tab 2. Survived mice after sc 7 chelating agents after ip NiCl_2 ($n = 10$).

Chelator/ $\text{g} \cdot \text{kg}^{-1}$		$\text{NiCl}_2/\text{mg} \cdot \text{kg}^{-1}$			
		70	140	250	500
		3	0	0	0
CBMIDA	1.5	10	10	10	10
	2.5	10	10	10	9
CDTA*	0.15	10	1	2	0
Dithiocarb	0.5	0	1	1	0
Edetic acid	0.15	10	8	2	0
Na-DMS	1	10	10	6	2
Penicillamine	0.3	10	10	0	0
Quamic acid	0.5	10	7	0	0

*1,2-cyclohexylene dinitrilotetraacetic acid




Fig 1. Autoradiograms from ♂ mice iv $^{63}\text{NiCl}_2$ alone or followed by CBMIDA 3 h after Ni (A) or Ni + CBMIDA (B); 8 h after Ni (C) or Ni + CBMIDA (D).

Effects of chelating agents on LD₅₀ of NiCl₂ Mice ($n = 260$, weighing $20.4 \pm s 1.5$ g) were divided into 5 groups. Control group was injected ip only NiCl₂ at various doses ($n = 10$). Other 4 groups were respectively injected sc: CBMIDA 1.5 or 2.5, Na-DMS 1, edetic acid $0.15 \text{ g} \cdot \text{kg}^{-1}$ after ip NiCl₂. The 3-d LD₅₀ (95 % confidence limits) were calculated by Finney's way.

After ip a single dose to mice, the LD₅₀ of nickel chloride was $82.7 \text{ mg} \cdot \text{kg}^{-1}$, they were immediately injected sc chelating agents, the LD₅₀ of NiCl₂ was raised as the following order: CBMIDA > Na-DMS > edetic acid (Tab 3).

Tab 3. LD₅₀ of ip NiCl₂ alone or followed by chelating agents.

Species	<i>n</i>	Chelator	Dose/ $\text{g} \cdot \text{kg}^{-1}$	Route	LD ₅₀ / $\text{mg} \cdot \text{kg}^{-1}$ (95 % confidence limits)
Mice	70	-	-	-	82.7 (76.9-88.9)
	50	CBMIDA	1.5	sc	789 (693-899)
	60		2.5	sc	820 (693-970)
	40	Edetic acid	0.15	sc	187 (152-230)
	40	Na-DMS	1	sc	310 (245-392)
Rats	50	-	-	-	38.8 (36.7-41.0)
	50	CBMIDA	0.5	im	332 (305-362)

Rats ($n = 100$, weighing $182 \pm s 21$ g) were divided into 2 groups. The toxic group was injected ip various doses of NiCl₂. The detoxification group was injected im CBMIDA $0.5 \text{ g} \cdot \text{kg}^{-1}$ after ip NiCl₂. The LD₅₀ of NiCl₂ was elevated from 39 to 332 $\text{mg} \cdot \text{kg}^{-1}$, about 8.6 times of that in toxic group (Tab 3).

Effect of CBMIDA on ⁶³Ni tissue distribution and elimination Mice (weighing $20.4 \pm s 0.5$ g) were divided into 2 groups, 10 mice/group. The control group was injected iv ⁶³NiCl₂ 185 kBq/mouse; the treated group was injected ip CBMIDA $1.5 \text{ g} \cdot \text{kg}^{-1}$ after iv ⁶³NiCl₂. Each mouse was kept in a metabolism cage for 24 h, and then killed. The heart, lung, brain, liver, spleen, kidney, bone, and blood were weighed, and 7-15 mg, were digested in 0.1 mL formic acid and 0.1 mL H₂O₂ at 80 °C for 30 min. Radioactivity was measured in 8 mL of 0.01 % POPOP and 0.4 % PPO with liquid scintillation counter for 1 min. In the CBMIDA-treated group, the contents of ⁶³Ni were reduced remarkably in blood and

lung, but increased in bone. ⁶³Ni in urine, feces, and other tissues were similar to those of control group at 24 h (Tab 4).

Tab 4. Tissue radioactivity at 24 h after iv ⁶³NiCl₂ 185 kBq and ip CBMIDA $1.5 \text{ g} \cdot \text{kg}^{-1}$ in mice $n = 10$. **P* > 0.05, ^c*P* < 0.01 vs control.

	Radioactivity (kBq/g wet tissue)	
	Control	CBMIDA
Blood (L)	967 ± 367	433 ± 100 ^c
Bone	0.52 ± 0.13	1.8 ± 0.7 ^c
Brain	0.55 ± 0.22	0.38 ± 0.18 ^a
Heart	0.60 ± 0.25	0.47 ± 0.22 ^a
Kidney	2.9 ± 1.1	2.8 ± 1.2 ^a
Liver	0.8 ± 0.4	0.7 ± 0.3 ^a
Lung	1.9 ± 0.5	0.55 ± 0.22 ^c
Spleen	1.1 ± 0.6	1.1 ± 0.8 ^a
Urine (24 h)	105 ± 33	109 ± 37 ^a
Feces (24 h)	15 ± 14	17 ± 16 ^a

Effect of CBMIDA on ⁶³Ni localization in mice

Mice ($n = 4$, weighing 28 g) injected iv ⁶³NiCl₂ 370 kBq/mouse were divided into 2 groups, 2 mice served as control, the other 2 mice were immediately injected ip CBMIDA $1.5 \text{ g} \cdot \text{kg}^{-1}$. At 3 and 8 h, respectively, 1 mouse in each group was anesthetized with ether, and frozen in mixture of dry ice and hexane (-75 °C). Autoradiography was made^[5]. Whole-body sections were made 20 μm in thickness, at -20 °C, the X-film was exposed for 43 wk for the 3-h group, and exposed for 48 wk for the 8-h group.

At 3 h after the mice were injected iv ⁶³NiCl₂, the concentrations were high in kidney, lung, and Harder's gland; moderate in bone, liver, skin, and blood. There were trace radioactivities in intestines (Fig 1A). In the CBMIDA-treated mice, the radioactivities were high in kidney, bone, and Harder's gland; moderate in lung, liver, and blood. Remarkable accumulation of ⁶³Ni was found in bone, and reduced in lung and skin (Fig 1B).

At 8 h, in general, radioactivities were reduced in tissues after iv ⁶³NiCl₂. The radioactivities were moderate in kidney, lung, blood, and urine, and low in bone, intestine, skin, and liver (Fig 1C). In CBMIDA-treated mice, the levels were increased in kidney, bone, intestine, and skin, but remarkably decreased in lung and blood (Fig 1D).

DISCUSSION

Antidote principle of chelating agent was to combine with metal ion to form complex with a lower toxicity, it reduced the metal ion to the target organs poisoned or enhanced the urinary excretion of the ion. The present study showed that CBMIDA markedly raised the survival rate of NiCl₂-poisoned mice and rats, but the excretion of ⁶³Ni through urine and feces was not increased at 24 h. The detoxifying effect of CBMIDA on nickel might be that the chelate was combined with nickel, to form complex of lower toxicity in body.

The tissue distribution and localization of ⁶³Ni were similar. The ⁶³Ni deposited in organs showed as the reports^[6], whereas given CBMIDA is more effective for removing nickel from lung, but to accumulate in bone. The metabolism of CBMIDA was mainly deposited in bone except the excretion^[7]. It might be that CBMIDA formed the complex of CBMIDA-Ni, and enhanced the ⁶³Ni content in bone due to its action in affinity bone.

In conclusion, CBMIDA markedly raised survival rate of nickel-poisoned mice and rats and decreased content of ⁶³Ni in lung and blood.

REFERENCES

- 1 Nieboer E, Rossetto FE, Menon CR. Toxicology of nickel compounds. In: Sigel H, Sigel A, editors. Metal ions in biological systems; vol 23. Nickel and its role in biology. New York; Marcel Dekker; 1988. p 359-402.
- 2 Tao ZQ, Xu XH, Yan XM, Chen ZJ, Zhang JS, Liang YY, et al. Pharmacological studies on catecholamic acid, an efficient chelating agent for metal mobilization. Pizen lek Sborn 1988; 56 Suppl: 95-7.
- 3 Tao ZQ, Xu XH, Yan XM, Chen ZJ, Zhang JS, Liang YY, et al. Detoxication and mobilization of uranium by catecholamic acid.

Acta Pharmacol Sin 1987; 8: 284-8.

- 4 Fukuda S, Iida H, Hseih YY, Chen WZ. Effect of CBMIDA [catechol-3, 6-bis(methyleiminodiacetic acid)] on removal of plutonium in rats. Hoken Butsuri 1992; 27: 11-5.
- 5 Waddekk WJ, Marlowe C. Autoradiography. In: Garrett ER, Hirtz JL, editors. Drug fate and metabolism: methods and techniques; vol 1. 1st ed. New York; Marcel Dekker; 1977. p 1-25.
- 6 Oskarsson A, Tjälve H. Autoradiography of nickel chloride and nickel carbonyl in mice. Acta Pharmacol Toxicol 1977; 41 Suppl 1: 158-9.
- 7 Zhang JS, Liang YY, Yan XM. Whole-body autoradiographic localization of catecholamic acid in mice. Acta Pharmacol Sin 1994; 15: 79-80.

80-84

双酚胺酸对小鼠和大鼠氯化镍解毒及分布的影响¹

严雪铭², 陶正琴, 梁猷毅, 陈振家, 张建时, 徐新华 (中国科学院上海药物研究所, 上海 200031, 中国)

R595.2

关键词 螯合剂; 双酚胺酸; 镍; 半数致死量; 放射自显影术; 组织分布

重金属中毒

目的: 研究双酚胺酸(CBMIDA)对氯化镍的解毒作用. 方法: NiCl₂中毒后, 立即给予CBMIDA, 记录动物存活数; 小鼠 iv ⁶³NiCl₂后给药, 测定 24 h 组织中⁶³镍; 用整体放射自显影术, 显示小鼠体内⁶³镍分布. 结果: sc CBMIDA 0.5-1.5 g·kg⁻¹对 ip NiCl₂ 500 mg·kg⁻¹有解毒作用; 小鼠 ip NiCl₂ LD₅₀为 82.8 mg·kg⁻¹, 给药 1.5 或 2.5 g·kg⁻¹, LD₅₀分别为 789 和 820 mg·kg⁻¹; 大鼠 im CBMIDA 500 mg·kg⁻¹使 NiCl₂ 的 LD₅₀提高 8 倍; 组织中⁶³镍测定和定位显示, CBMIDA 减少肺和血液中⁶³镍, 增加了骨中⁶³镍, 24 h 尿、粪⁶³镍排出与对照组无明显差异. 结论: CBMIDA 有效地解除镍毒性, 提高动物存活率, 降低镍在肺部的滞留.